SuperworthRigel Pharmaceuticals market cap RIGL
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $899.1M
- Highest close in our data
- $916.8M
- Oct 2026
Rigel Pharmaceuticals is worth $899.1M at the close on Oct 23, 2026, at $48.13 a share.
That is up 67% over the last year and up 57% over five years.
Its highest close in our data was $916.8M in Oct 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $899.1M | $476.8M | $916.8M | +13% |
| 2025 | $798.8M | $286.2M | $916.5M | +175% |
| 2024 | $290.6M | $136.5M | $486.4M | +15% |
| 2023 | $252.8M | $127.3M | $345.7M | −2% |
| 2022 | $259.3M | $115.8M | $592.3M | −43% |
| 2021 | $453.2M | $410.4M | $787.5M | −23% |
| 2020 | $591.4M | $222.5M | $632M | +70% |
| 2019 | $348.6M | $274M | $436.4M | −7% |
| 2018 | $373.3M | $356.6M | $664.1M | −34% |
| 2017 | $568.4M | $195.9M | $622.6M | +141% |
| 2016 | $235.5M | $176.6M | $370.8M | −12% |
| 2015 | $268.2M | $181.7M | $429.2M | +33% |
| 2014 | $201M | $150.1M | $405.2M | −16% |
| 2013 | $239.6M | $216M | $643.1M | −57% |
| 2012 | $552.5M | $512.3M | $800.3M | −2% |
| 2011 | $562.1M | $475.9M | $591.2M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Rigel Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| RIGLRigel Pharmaceuticals | $899.1M |
| ABUSArbutus Biopharma | $831M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| COLLCollegium Pharmaceutical | $747.5M |
| OMEROmeros | $1.2B |
| CRMDCorMedix | $611.9M |
| ZVRAZevra Therapeutics | $582.6M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| PBYIPuma Biotechnology | $568.9M |
| PCRXPacira BioSciences | $1.5B |
| ANABAnaptysbio | $1.5B |
| Peer median | $789.2M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Rigel Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.